F-star Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eliot Richard Forster
- Full Time Employees
- 84
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Eddeva B920 Cambridge United Kingdom CB22 3AT
- IPO Date
- May 7, 2021
- CIK
- 0001566373
- Website
- f-star.com
- Similar Companies
- Business
- F-Star Therapeutics, Inc. (FSTX) is a clinical-stage biopharmaceutical company focused on developing next-generation multispecific immunotherapies, particularly tetravalent mAb2 bispecific antibodies and STING agonists, to treat cancer patients with limited options by reactivating the immune system against tumors. Founded in 2002 and headquartered at the Babraham Research Campus in Cambridge, United Kingdom, the company engineers its proprietary modular antibody technology to enable simultaneous targeting of immune checkpoints and costimulatory receptors; its lead clinical pipeline includes FS118, a first-in-class LAG-3/PD-L1 bispecific antibody in Phase 2 proof-of-concept trials for PD-1/PD-L1 acquired resistance head and neck cancer and checkpoint-naïve non-small cell lung cancer plus diffuse large B-cell lymphoma; FS120, a first-in-class OX40/CD137 dual agonist bispecific antibody in Phase 1 trials to enhance standard-of-care outcomes; FS222, a CD137/PD-L1 bispecific antibody in Phase 1 trials targeting PD-L1 low tumors; and SB 11285, a second-generation intravenous STING agonist in Phase 1 monotherapy and combination studies with atezolizumab. F-Star operates primarily in Europe and the United States through its clinical programs and maintains partnerships with multinational pharmaceutical companies, including a recent license agreement with Takeda for a novel immuno-oncology bispecific antibody. In a major strategic shift, invoX Pharma, a subsidiary of Sino Biopharmaceutical, completed its $161 million acquisition of F-Star in March 2023 to bolster its oncology pipeline, but F-Star transitioned to operate as an independent private company by early 2025, enabling focused advancement of its differentiated bispecific platform amid ongoing Phase 1 and 2 trials.
F-star's Delayed Acquisition Presents A Risky Opportunity
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
New Strong Buy Stocks for July 15th
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
F-star Therapeutics Shares Are Rallying Today - Read Why
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
F-star Therapeutics to Participate in Upcoming Investor Conferences
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q2 2021 Results - Earnings Call Transcript
Why F-star Therapeutics (FSTX) Might Surprise This Earnings Season
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates